Investor Relations

Company Overview

DehydraTECH™ is Lexaria’s patented drug delivery-enabling platform technology which improves the absorption of active pharmaceutical ingredients (APIs) into the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of API’s mainly in oral formats, including GLP-1 drugs. DehydraTECH has even evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds (i.e., compounds that act principally upon targets in the central nervous system). Lexaria operates a licensed in-house formulation development and research laboratory and holds a robust intellectual property portfolio with 46 patents granted and many more patents pending worldwide.

View Management TeamView Board of Directors